ICU Medical, Inc. $ICUI Shares Sold by Fuller & Thaler Asset Management Inc.

Key Points

• Fuller & Thaler Asset Management Inc. holds a $192.07 million stake in ICU Medical, Inc., accounting for 0.7% of its portfolio after reducing its holdings by 0.8% in the first quarter.
• CEO Vivek Jain purchased 21,929 shares for approximately $2.47 million, representing a 20.26% increase in his ownership, while COO Christian B. Voigtlander sold 4,985 shares.
• ICU Medical reported an EPS of $2.10 for the last quarter, exceeding expectations, but revenues decreased by 8.0% year-over-year, indicating challenges despite beating earnings forecasts.

Fuller & Thaler Asset Management Inc. trimmed its stake in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 0.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,383,223 shares of the medical instruments supplier's stock after selling 11,455 shares during the period. ICU Medical comprises 0.7% of Fuller & Thaler Asset Management Inc.'s holdings, making the stock its 26th biggest holding. Fuller & Thaler Asset Management Inc. owned about 5.62% of ICU Medical worth $192,074,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in ICUI. GAMMA Investing LLC boosted its position in ICU Medical by 17,559.7% in the 1st quarter. GAMMA Investing LLC now owns 99,424 shares of the medical instruments supplier's stock valued at $138,060,000 after buying an additional 98,861 shares during the period. Point72 Asset Management L.P. boosted its position in ICU Medical by 63.2% in the 4th quarter. Point72 Asset Management L.P. now owns 245,340 shares of the medical instruments supplier's stock valued at $38,069,000 after buying an additional 95,030 shares during the period. Pacific Capital Partners Ltd purchased a new stake in ICU Medical in the 1st quarter valued at about $12,845,000. Invesco Ltd. boosted its position in ICU Medical by 80.1% in the 1st quarter. Invesco Ltd. now owns 203,827 shares of the medical instruments supplier's stock valued at $28,303,000 after buying an additional 90,674 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in ICU Medical by 18.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 539,981 shares of the medical instruments supplier's stock valued at $83,788,000 after buying an additional 82,982 shares during the period. 96.10% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CEO Vivek Jain acquired 21,929 shares of the business's stock in a transaction dated Thursday, August 14th. The shares were acquired at an average cost of $112.84 per share, with a total value of $2,474,468.36. Following the completion of the acquisition, the chief executive officer owned 130,149 shares of the company's stock, valued at approximately $14,686,013.16. This trade represents a 20.26% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO Christian B. Voigtlander sold 4,985 shares of the firm's stock in a transaction dated Wednesday, May 28th. The stock was sold at an average price of $128.50, for a total value of $640,572.50. Following the completion of the transaction, the chief operating officer owned 6,088 shares of the company's stock, valued at approximately $782,308. The trade was a 45.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.50% of the stock is owned by insiders.

ICU Medical Stock Up 5.3%

Shares of NASDAQ ICUI traded up $6.43 during trading hours on Friday, hitting $128.18. 275,296 shares of the stock were exchanged, compared to its average volume of 268,507. The company has a quick ratio of 1.17, a current ratio of 2.44 and a debt-to-equity ratio of 0.63. The company has a market cap of $3.16 billion, a PE ratio of -84.33 and a beta of 0.88. The firm has a fifty day moving average price of $127.24 and a 200-day moving average price of $137.28. ICU Medical, Inc. has a 12 month low of $107.00 and a 12 month high of $196.26.

ICU Medical (NASDAQ:ICUI - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $2.10 EPS for the quarter, topping the consensus estimate of $1.44 by $0.66. The firm had revenue of $543.57 million during the quarter, compared to analyst estimates of $543.33 million. ICU Medical had a negative net margin of 1.56% and a positive return on equity of 7.24%. ICU Medical's revenue was down 8.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.56 EPS. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. On average, sell-side analysts expect that ICU Medical, Inc. will post 4.11 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Raymond James Financial lowered their price objective on shares of ICU Medical from $187.00 to $180.00 and set a "strong-buy" rating for the company in a research report on Friday, August 8th. Piper Sandler started coverage on shares of ICU Medical in a research report on Friday, August 15th. They issued an "overweight" rating and a $145.00 price target for the company. Finally, Wall Street Zen cut shares of ICU Medical from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, ICU Medical has an average rating of "Buy" and a consensus target price of $179.00.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.